ATEC Reports First Quarter Financial Results and Recent Corporate Highlights

Rhea-AI Summary

Alphatec Holdings (ATEC) reported a robust 50% revenue growth for Q1 2021, totaling $44.1 million, with U.S. revenue at $43.7 million and a gross margin of 73.1%. The company is experiencing market expansion, with new products contributing to 77% of U.S. revenue. ATEC anticipates full-year revenues of approximately $190 million, driven by continued innovation and product launches, despite an expected 33% growth in U.S. revenue due to the winding down of an international supply agreement.

Positive

• 50% revenue growth in Q1 2021 reaching $44.1 million.
• 77% of U.S. revenue now from new products, up from 56% in Q1 2020.
• Secured clearance for EOS imaging acquisition, enhancing clinical capabilities.

Negative

• Operating loss of $19 million reported for Q1 2021.
• Anticipated wind-down of international supply agreement affecting revenue.

• U.S. Revenue Growth Accelerates to 50%
  
  
• Revenue Growth Averages ~33% Over Past Eight Quarters

CARLSBAD, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2021, and recent corporate highlights.

First Quarter 2021 Financial Results

	Quarter Ended March 31, 2021
Total revenue	$44.1 million
U.S. revenue	$43.7 million
U.S. gross margin	73.1%
Non-GAAP U.S. gross margin	77.9%
Operating expenses	$50.9 million
Non-GAAP operating expenses	$42.0 million
Operating loss	($19.0) million
Non-GAAP adjusted EBITDA	($4.1) million
Ending cash balance	$191.1 million

Recent Highlights

• Expanded contribution from new products to 77% of U.S. revenue, up from 56% in Q1 2020;
• Continued sales network transformation delivering 60% year-over-year revenue growth from strategic distribution;
• Secured clearance from French regulatory authority for tender offer to acquire EOS imaging, S.A. (“EOS”), allowing the transaction – which will advance ATEC clinical prowess with improved information from diagnosis to follow-up – to move forward.
  

“With revenue growth of 50% in the first quarter, ATEC’s market share expansion continues,” said Pat Miles, Chairman and Chief Executive Officer. “Our relentless focus on improving the clinical experience in spine is now propelling industry-leading growth. Market-shaping innovation, integrated with unprecedented intra-operative information, is compelling an increasing number of surgeons and exclusive distributors to partner with ATEC. That growth is being amplified as the introduction of distinct products and procedures throughout our portfolio increases revenue per surgery and inspires broader adoption. Still, there is vast opportunity ahead of us to advance spine surgery, and as spine’s most experienced students, we know that ATEC’s best is yet to come!”

Financial Outlook for the Full Year 2021

The Company expects total revenue for the fiscal year ended December 31, 2021, to approximate $190 million, which includes U.S. revenue of approximately $188 million. Revenue guidance reflects expected U.S. revenue growth of roughly 33% compared to 2020, driven by continued launches of novel procedures, products, and the revitalization of the Company’s distribution network. Total revenue guidance contemplates the anticipated wind-down of the Company’s international supply agreement on August 31, 2021. ATEC expects to update guidance to reflect the positive impact of EOS imaging when the Company reports second quarter 2021 financial results, once the transaction is finalized.

Investor Conference Call

ATEC will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast can be accessed by visiting the Investor Relations section of ATEC’s corporate website at https://investors.alphatecspine.com/investors.

To dial in to the webcast, please visit the following registration link: http://www.directeventreg.com/registration/event/9350774. Once registered, participants will be provided with access details and a registrant ID.

A replay of the webcast will remain available through the Investor Relations section of ATEC’s Corporate Website at https://investors.alphatecspine.com for twelve months. In addition, a replay of the audiocast will be available beginning two hours after the call’s completion until May 13, 2021. The replay dial-in numbers are (800)585-8367 for domestic callers and (416)621-4642 for international callers. Please use the replay conference ID number 9350774.

Non-GAAP Financial Information

To supplement the Company’s financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP U.S. gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP Adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

Forward Looking Statements 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company’s revenue and growth outlook, planned commercial launches, product introduction and surgeon adoption, salesforce revitalization and growth of strategic distribution network, turning the Company into a growth organization, creating future market disruption and market share expansion, the Company’s future ability to finance its operations and statements about the anticipated acquisition (and potential impacts therefrom) of EOS imaging, S.A.  Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the impact of COVID-19 pandemic on the Company's business and the economy; the uncertainty of success in developing new products or products currently in the Company’s pipeline; the uncertainties in the Company’s ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for Company’s products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company’s ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company’s ability to compete with other products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any litigation asserted against the Company; and uncertainties and risks related to the proposed tender offer EOS Imaging, S.A. and integration thereafter. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. 

Investor/Media Contact:

Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com

Company Contact:
J. Todd Koning
Chief Financial Officer  
investorrelations@atecspine.com

ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
		Three Months Ended
		March 31,
			2021				2020
		(unaudited)				(unaudited)
	Revenues:
	Revenue from U.S. products	$	43,716			$	29,070
	Revenue from international supply agreement		405				1,045
	Total revenues		44,121				30,115
	Cost of revenues		12,263				9,084
	Gross profit		31,858				21,031
	Operating expenses:
	Research and development		5,801				4,170
	Sales, general and administrative		40,426				27,582
	Litigation-related		3,335				2,643
	Amortization of acquired intangible assets		172				172
	Transaction-related		1,012				4,272
	Restructuring		158				—
	Total operating expenses		50,904				38,839
	Operating loss		(19,046	)			(17,808	)
	Interest and other expense, net:
	Interest expense, net		(1,938	)			(2,874	)
	Other expenses		(1,889	)			—
	Total interest and other expenses, net		(3,827	)			(2,874	)
	Loss from continuing operations before taxes		(22,873	)			(20,682	)
	Income tax provision		30				40
	Loss from continuing operations		(22,903	)			(20,722	)
	Net loss	$	(22,903	)		$	(20,722	)
	Net loss per share, basic and diluted	$	(0.26	)		$	(0.33	)
	Shares used in calculating basic and diluted net loss per share		87,223				62,568
	Stock-based compensation included in:
	Cost of revenues	$	95			$	107
	Research and development		498				390
	Sales, general and administrative		3,881				3,071
		$	4,474			$	3,568

ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
	March 31, 2021			December 31, 2020
	(unaudited)
ASSETS
Current assets:
Cash	$	191,137		$	107,765
Accounts receivable, net		25,751			23,527
Inventories, net		57,376			46,001
Prepaid expenses and other current assets		3,433			5,439
Withholding tax receivable from Officer		1,076			1,076
Current assets of discontinued operations		348			352
Total current assets		279,121			184,160
Property and equipment, net		56,124			36,670
Right-of-use asset		21,704			1,177
Goodwill		13,897			13,897
Intangible assets, net		24,129			24,720
Debt securities		1,313			—
Equity securities		7,619			—
Other assets		541			541
Noncurrent assets of discontinued operations		55			58
Total assets	$	404,503		$	261,223
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	26,416		$	17,599
Accrued expenses		36,730			35,231
Current portion of long-term debt		5,374			4,200
Current portion of lease liability		1,486			885
Current liabilities of discontinued operations		143			397
Total current liabilities		70,149			58,312
Total long term liabilities		70,621			49,428
Redeemable preferred stock		23,603			23,603
Contingently redeemable common stock		131,838			—
Stockholders' equity		108,292			129,880
Total liabilities and stockholders' equity	$	404,503		$	261,223
		-			-

ALPHATEC HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in thousands)
			Three Months Ended
			March 31,
				2021				2020
			(unaudited)				(unaudited)
	Operating expenses		$	50,904			$	38,839
	Adjustments:
	Stock-based compensation			(4,379	)			(3,461	)
	Litigation-related expenses			(3,335	)			(2,643	)
	Restructuring expenses			(158	)			—
	Transaction-related expenses			(1,012	)			(4,272	)
	Non-GAAP operating expenses		$	42,020			$	28,463
			Three Months Ended
			March 31,
				2021				2020
			(unaudited)				(unaudited)
	Operating loss, as reported		$	(19,046	)		$	(17,808	)
	Add back significant items:
	Stock-based compensation			4,474				3,568
	Litigation-related expenses			3,335				2,643
	Restructuring expenses			158				—
	Transaction-related expenses			1,012				4,272
	Excess & obsolete charges			2,096				1,722
	Adjusted operating loss			(7,971	)			(5,603	)
	Operating loss, as reported		$	(19,046	)		$	(17,808	)
	Depreciation			3,409				2,014
	Amortization of intangible assets			441				440
	EBITDA			(15,196	)			(15,354	)
	Add back significant items:
	Stock-based compensation			4,474				3,568
	Litigation-related expenses			3,335				2,643
	Restructuring expenses			158				—
	Transaction-related expenses			1,012				4,272
	Excess & obsolete charges			2,096				1,722
	Adjusted EBITDA		$	(4,121	)		$	(3,149	)

ALPHATEC HOLDINGS, INC.
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS PROFIT
(in thousands, except percentages)
		Three Months Ended
		March 31,
			2021				2020
	Revenues by source	(unaudited)				(unaudited)
	Revenue from U.S. products	$	43,716			$	29,070
	Revenue from international supply agreement		405				1,045
	Total revenues	$	44,121			$	30,115
	Gross profit (loss) by source
	Gross profit from U.S. products	$	31,975			$	20,954
	Gross profit (loss) from international supply agreement		(117	)			77
	Total gross profit	$	31,858			$	21,031
	Gross profit (loss) margin by source
	Gross profit margin from U.S. products		73.1	%			72.1	%
	Gross profit (loss) margin from international supply agreement		-28.9	%			7.4	%
	Total gross profit margin		72.2	%			69.8	%
	RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND GROSS MARGIN FROM U.S. PRODUCTS
(in thousands, except percentages)
		Three Months Ended
		March 31,
			2021				2020
		(unaudited)				(unaudited)
	GAAP-based gross profit from U.S. products	$	31,975			$	20,954
	Add: non-cash excess and obsolete charges		2,096				1,722
	Non-GAAP gross profit from U.S. products	$	34,071			$	22,676
	GAAP-based gross margin from U.S. products		73.1	%			72.1	%
	Add: non-cash excess and obsolete charges		4.8	%			5.9	%
	Non-GAAP gross margin from U.S. products		77.9	%			78.0	%

 

 

 

FAQ

What was Alphatec Holdings' revenue for Q1 2021?

Alphatec reported a total revenue of $44.1 million for Q1 2021.

How much did U.S. revenue grow for ATEC in the first quarter of 2021?

U.S. revenue for Alphatec grew by 50% in Q1 2021, amounting to $43.7 million.

What is Alphatec's revenue guidance for 2021?

ATEC expects total revenue for 2021 to be approximately $190 million, with U.S. revenue around $188 million.

What is the significance of the EOS imaging acquisition for ATEC?

The acquisition of EOS imaging is expected to enhance ATEC's clinical capabilities, providing improved diagnostic information.

Did Alphatec Holdings report any operating losses?

Yes, ATEC reported an operating loss of $19 million in Q1 2021.